Case number 1:19-cv-04876
Keryx Biopharmaceuticals, Inc. et al v. PAR Pharmaceutical, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Sep 6, 2019 | N/A | Notice to Attorney to Re-File Document - Event Type Error (0) Docket Text:***NOTICE TO ATTORNEY TO RE-FILE DOCUMENT - EVENT TYPE ERROR. Notice to Attorney Robert Gunther to RE-FILE Document [12] Stipulation of Voluntary Dismissal. Use the event type Other Filings, Proposed Orders, Proposed Stipulation and Order. (km) |
| Sep 6, 2019 | 12 | Stipulation of Voluntary Dismissal (2) Docket Text: FILING ERROR - WRONG EVENT TYPE SELECTED FROM MENU - STIPULATION OF VOLUNTARY DISMISSAL It is hereby stipulated and agreed by and between the parties and/or their respective counsel(s) that the above-captioned action is voluntarily dismissed, without prejudice against the defendant(s) PAR Pharmaceutical, Inc. and without costs pursuant to Rule 41(a)(1)(A)(ii) of the Federal Rules of Civil Procedure. Document filed by Keryx Biopharmaceuticals, Inc., Panion & BF Biotech, Inc.. Proposed document to be reviewed and processed by Clerk's Office staff (No action required by chambers)..(Gunther, Robert) Modified on 9/6/2019 (km). |
| Sep 6, 2019 | 13 | Proposed Stipulation and Order (2) Docket Text: PROPOSED STIPULATION AND ORDER. Document filed by Keryx Biopharmaceuticals, Inc., Panion & BF Biotech, Inc.. (Gunther, Robert) |
| Sep 6, 2019 | 14 | Stipulation and Order of Voluntary Dismissal (2) Docket Text: STIPULATION AND ORDER OF DISMISSAL: Plaintiffs Keryx Biopharmaceuticals, Inc. and Panion & BF Biotech, Inc., and Defendant Par Pharmaceutical, Inc., by their respective undersigned counsel, hereby STIPULATE and AGREE as follows: 1. Pursuant to Rule 41(a)(1)(A)(ii), all claims and counterclaims, defenses, motions and petitions asserted in this Action are dismissed without prejudice; 2. Each party shall bear its own costs and attorneys' fees with respect to the matters dismissed hereby; 3. The parties each expressly waive any right to appeal or otherwise move for relief from this Stipulation and Order; 4. This Court retains jurisdiction over the parties for purposes of enforcing this Stipulation and Order; and 5. This Stipulation and Order shall finally resolve the Action between the parties. The Clerk of the Court is directed to enter this Stipulation and Order forthwith. (Signed by Judge Edgardo Ramos on 9/6/2019) (mro) |
| Sep 6, 2019 | 15 | AO 120 Form Patent - Case Terminated - Submitted (1) Docket Text: AO 120 FORM PATENT - CASE TERMINATED - SUBMITTED. In compliance with the provisions of 35 U.S.C. 290, the Director of the U.S. Patent and Trademark Office is hereby advised that a final decision was rendered on 9/6/19 in a court action filed on the following patent(s) in the U.S. District Court Southern District of New York. Director of the U.S. Patent and Trademark Office electronically notified via Notice of Electronic Filing (NEF). (mro) |
| Aug 7, 2019 | 11 | Stipulation and Order (2) Docket Text: STIPULATION AND ORDER, It is hereby stipulated, subject to the approval of the Court, that: 1. Litigation between the parties with respect to the Claims, motions, demands and petitions is stayed for thirty (30) days to permit review of the settlement agreement by certain government authorities; and 2. If the parties have not filed a stipulation of dismissal of the Claims, motions, demands and petitions within that thirty (30) day period, they shall contact the Court to report on the status of the settlement. SO ORDERED. Case stayed. (Signed by Judge Edgardo Ramos on 8/7/2019) (kv) |
| Aug 5, 2019 | 10 | Proposed Stipulation and Order (2) Docket Text: PROPOSED STIPULATION AND ORDER. Document filed by Keryx Biopharmaceuticals, Inc., Panion & BF Biotech, Inc.. (Gunther, Robert) |
| May 28, 2019 | N/A | Case Opening Initial Assignment Notice (0) Docket Text: CASE OPENING INITIAL ASSIGNMENT NOTICE: The above-entitled action is assigned to Judge Edgardo Ramos. Please download and review the Individual Practices of the assigned District Judge, located at http://nysd.uscourts.gov/judges/District. Attorneys are responsible for providing courtesy copies to judges where their Individual Practices require such. Please download and review the ECF Rules and Instructions, located at http://nysd.uscourts.gov/ecf_filing.php. (pne) |
| May 28, 2019 | N/A | Case Designation (0) Docket Text: Magistrate Judge Debra C. Freeman is so designated. Pursuant to 28 U.S.C. Section 636(c) and Fed. R. Civ. P. 73(b)(1) parties are notified that they may consent to proceed before a United States Magistrate Judge. Parties who wish to consent may access the necessary form at the following link: http://nysd.uscourts.gov/forms.php. (pne) |
| May 28, 2019 | N/A | Case Designated ECF (0) Docket Text: Case Designated ECF. (pne) |
| May 28, 2019 | N/A | Case Designated Patent Pilot Program (0) Docket Text: Case Eligible for Patent Pilot Program. (pne) |
| May 28, 2019 | 8 | Summons Issued (2) Docket Text: ELECTRONIC SUMMONS ISSUED as to PAR Pharmaceutical, Inc.. (pne) |
| May 28, 2019 | 9 | Mail Patent Form (case opening) (1) Docket Text: AO 120 FORM PATENT - CASE OPENING - SUBMITTED. In compliance with the provisions of 35 U.S.C. 290, the Director of the U.S. Patent and Trademark Office is hereby advised that a court action has been filed on the following patent(s) in the U.S. District Court Southern District of New York. Director of the U.S. Patent and Trademark Office electronically notified via Notice of Electronic Filing (NEF). (pne) |
| May 24, 2019 | 1 | Complaint (9) |
| May 24, 2019 | 1 | Exhibit A - 423 patent (36) |
| May 24, 2019 | 1 | Exhibit B - 191 patent (29) |
| May 24, 2019 | 2 | Civil Cover Sheet (2) Docket Text: CIVIL COVER SHEET filed. (Gunther, Robert) |
| May 24, 2019 | 3 | Request for Issuance of Summons (2) Docket Text: REQUEST FOR ISSUANCE OF SUMMONS as to Par Pharmaceutical, Inc., re: [1] Complaint,. Document filed by Keryx Biopharmaceuticals, Inc., Panion & BF Biotech, Inc.. (Gunther, Robert) |
| May 24, 2019 | 4 | Rule 7.1 Corporate Disclosure Statement (2) Docket Text: RULE 7.1 CORPORATE DISCLOSURE STATEMENT. Identifying Corporate Parent Akebia Therapeutics, Inc. for Keryx Biopharmaceuticals, Inc.. Document filed by Keryx Biopharmaceuticals, Inc..(Gunther, Robert) |
| May 24, 2019 | 5 | Rule 7.1 Corporate Disclosure Statement (2) Docket Text: RULE 7.1 CORPORATE DISCLOSURE STATEMENT. No Corporate Parent. Document filed by Panion & BF Biotech, Inc..(Gunther, Robert) |
| May 24, 2019 | 6 | AO 120 Form Patent/Trademark - Notice of Submission by Attorney (1) Docket Text: AO 120 FORM PATENT - NOTICE OF SUBMISSION BY ATTORNEY. AO 120 Form Patent/Trademark for case opening submitted to court for review.(Gunther, Robert) |
| May 24, 2019 | 7 | Notice of Appearance (1) Docket Text: NOTICE OF APPEARANCE by Timothy Andrew Cook on behalf of Keryx Biopharmaceuticals, Inc., Panion & BF Biotech, Inc.. (Cook, Timothy) |
| May 24, 2019 | 1 | Main Document (9) Docket Text: COMPLAINT against PAR Pharmaceutical, Inc.. (Filing Fee $ 400.00, Receipt Number ANYSDC-16953771)Document filed by Keryx Biopharmaceuticals, Inc., Panion & BF Biotech, Inc.. (Attachments: # (1) Exhibit A - 423 patent, # (2) Exhibit B - 191 patent)(Gunther, Robert) |
| May 24, 2019 | 1 | Complaint* (1) |
